Palvella Therapeutics Announces 2024 Annual Meeting Results and Equity Plan Amendment

On June 10, 2026, Palvella Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where several key proposals were approved. Stockholders elected George M. Jenkins, Todd C. Davis, and John Doux, M.D. as Class III directors to serve until the 2029 Annual Meeting. Additionally, stockholders approved an amendment to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan, increasing the number of authorized shares issuable by 750,000, bringing the maximum shares available for awards to 4,090,639 (subject to certain adjustments). Other approved matters included the ratification of Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year and the advisory approval of executive compensation for 2025. Stockholders also favored an annual frequency for future advisory votes on executive compensation. The meeting saw the participation of shareholders representing approximately 11.57 million shares out of 14.32 million outstanding. The 8-K filing confirms these corporate governance updates and the immediate effectiveness of the equity plan amendment following the vote.